The UK NSC recommendation on Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD) screening in newborns (currently in consultation)


This recommendation is currently being reviewed as part of the UK NSC's regular review cycle of all policies.

The review process began in Dec 2015 and is estimated to be completed by Feb 2017.

» Download the expert review for MCADD (PDF document, 259KB)

The UK NSC welcomes comments and feedback on the expert review during the consultation period that lasts from 17/08/2016 until 17/11/2016. Please send comments to Screening Evidence by e-mail using this feedback form.

Please note that all consultation submissions will be published on this page when the review is complete. Full details can be found in the confidentiality and disclosure section at the bottom of this page.

Recommendation Systematic population screening programme recommended

Evidence to support continuation or cessation of existing screening programmes should be reviewed regularly. The process for this is currently being revised, which is why this topic does not currently have a review date. The new process will be published in due course. Each programme has an active portfolio of research, evidence and audit to support continual improvement. Find out more about MCADD screening, as part of the newborn blood spot screening programme in England.


Find general information about population health screening.

More about MCADD

Fatty acids are one of the body's fuels: oxidation is the process by which they are broken down to release energy. This process has many steps, each catalysed by a different enzyme. Fatty acid oxidation (FAO) disorders result from deficiency of one of these enzymes.

MCADD is the commonest FAO disorder, affecting between 1 in 10,000 and 1 in 20,000 newborn babies.

Patients with MCADD deficiency are healthy most of the time. Infections or prolonged fasting, however, can lead to drowsiness and coma or sudden death. MCADD is treated through dietary management.

Further information about MCADD and its management can be found in the "Newborn screening for medium chain acyl CoA dehydrogenase deficiency" article, which can be downloaded from the 'related documents' section on this page.

» Read more about MCADD on NHS Choices

Screening in the UK

Compare how screening is offered across the UK.


British Dietetic Association
British Inherited Metabolic Disease Group
The British Society for Human Genetics
Children Living with Inherited Metabolic Diseases
Clinical Genetics Society
Genetic Alliance UK
Institute of Child Health
Rare Disease UK
Royal College of General Practitioners
Royal College of Midwives
Royal College of Paediatrics and Child Health
Royal College of Pathologists
Royal College of Physicians
Save Babies Through Screening Foundation UK
Specialised Healthcare Alliance

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

Recommendation Review History

On 7 February 2007, the English Health Minister announced that all newborn babies in England are to be offered screening for MCADD by March 2009.

As of February 2009, all babies in England are offered screening for MCADD and a reception was held in March 2009 at the Houses of Parliament to launch this successful implementation. See the UCL Institute of Child Health press release.

The full report into prevalence, predictive value and test validity of screening for MCADD, based on 1.5 million babies, was published in 2011 and can be found here.  

Related documents

icon MCADD Pilot Study Summary (PDF document, 119KB, 22/01/15)

Confidentiality and disclosure

Information provided in response to this consultation, including personal information, may be subject to publication or release to other parties or to disclosure in accordance with the access to information regimes (these are primarily the Freedom of Information Act 2000, the Data Protection Act 1998, and the Environmental Information Regulations 2004). If you want information, including personal data that you provide to be treated as confidential, please be aware that, under the FOIA, there is a statutory Code of Practice with which public authorities must comply and which deals, amongst other things, with obligations of confidence.

In view of this it would be helpful if you could explain to us why you regard the information you have provided as confidential. If we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. An automatic confidentiality disclaimer generated by your IT system will not, of itself, be regarded as binding on the UK National Screening Committee.

Any request for information to be treated in confidence will be taken into consideration in the publication of responses to the consultation. The UK National Screening Committee intends to publish all responses following the closure of the consultation period, however we will not publish responses from respondents who request that any of the information in their response, including personal data, should be handled in confidence. The UK National Screening Committee reserves the right not to publish or take into account any representations which are openly offensive or defamatory.

More options

Go to top